September 21, 2021 7:44am

Poor liquidity and risk have had built on market instability

Pre-open indications: 5 BUY and 1 SELLs

What I provide is an intelligence daily. RMi outlines the prelude to the daily dose of facts and objectivity!

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.86% (+291 points), S&P futures are UP +0.79% (+35 point) and NASDAQ futures are UP +0.75% (+112 point)

 

U.S. stock futures are bouncing on Tuesday as investors are about to buy the dips,

European stocks were trading higher,

Asia-Pacific shares were mixed, with markets in mainland China and South Korea closed on Tuesday for a holiday as Japan flailed.

 

Data Docket: The Fed begins its two-day policy meeting specifically about tapering its bond buying and when it will commence.

  • Wednesday will bring the results of the Fed's policy meeting, where the central bank is expected to lay the groundwork for a tapering, although the consensus is for an actual announcement to be delayed until the November or December meetings.

 

Henry’omics:

The Dow (-1.8%), the S&P (-1.7%) and Nasdaq (-2.2%) tumbled on Monday due to multiple alarms including the imminent Fed meeting, the lingering delta variant, potential economic disruption in China and the up-coming debt ceiling deadline.

The Cboe Volatility index, i.e., fear gauge, jumped above the 26 level on Monday, the highest since May.

Key element, the Nasdaq broke down sharply below its 50-day line Monday, adding more selling pressure to the major stock indexes.

Note:  FDA Panel Is a win for Pfizer (PFE) vaccine despite mixed and positive results in kids

 

If you didn’t remember what happen at Monday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

  • Monday’s evening’s recap: “The stem, cell and gene therapy sector is vulnerable to extreme market moves, overbought and oversold categories as risk stimulates the susceptibility!” …  https://www.regmedinvestors.com/articles/12102

Q3/21:

  • September, 1 holiday, 6 positive and 7 negative close
  • August - 12 positive and 10 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

Applied Genetic Technologies (AGTC) – reports Thursday, 9/23

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles: WHAT happened to the usual “pump/promote”?

  • Monday closed down -$0.26 to $3.40 with 563 shares traded after last Friday’s 129 shares traded dropping the share price -$0.38 after Thursday closed -$0.04 with 14,641 shares traded

Question: WERE BSTG’s Q2 filing AUDITED by any accounting firm or left UNAUDITED for investors?

 

BUY:

CELLECTIS SA (CLLS) closed -$0.93 TO $13.50 and has appositive +$0.13 or +0.96% aftermarket indication.

CRISP Therapeutics (CRSP) closed down -$8.05 to $116.47 after Friday’s +$7.10 to $124.52 and has a positive +$2.09 or +1.79% pre-market indication.

Intellia Therapeutics (NTLA) closed down -$8.93 to $148.36 after Friday’s +$3.44 to $157.29 and has a positive +$2.64 or +1.78% pre-open indication,

Solid Biosciences (SLDB) closed down -$0.14 to $2.66 after Friday’s $2.80 and has a positive +$0.16 or +6.02% pre-open indication on so-far undivulged presentation of long-term data from patients 4-6 in the ongoing IGNITE DMD P1/2 clinical trial of SGT-001 in patients with Duchenne,

Editas Medicine (EDIT) closed down -$5.00 to $58.20 after Friday’s +$2.20 to $63.20 and has a positive +$1.20 or +2.06% pre-open indication,

 

The BOTTOM LINE: The bandages are on, the pain has subsided and slow movment is the way to move ...

Not yielding, I keep reinforcing the theme that increased stock market volatility suppresses the stem, cell and gene therapy sector.

I maintain, the recent stem, cell and gene therapy sector investors should be a bit more defensive, limiting new buys and perhaps curtailing overexposure.

Theme is uncertainty, more likely to me: skepticism …

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.